Company Overview and News

 
Rhinomed shares rise as new substantial shareholder revealed

2018-03-29 proactiveinvestors.com.au
Rhinomed Ltd (ASX:RNO) is one of the top performing companies on the ASX today with shares up 25% intra-day around midday.

 
Rhinomed attracts funding to accelerate growth of its anti-snoring device

2017-11-29 proactiveinvestors.com.au
Rhinomed Ltd (ASX:RNO) has completed a $3.6 million share placement to institutional and sophisticated investors at $0.15 per share.

 
Rhinomed takes its nasal breathing product into the Taiwanese market

2017-09-14 proactiveinvestors.com.au
Rhinomed Ltd (ASX:RNO) has signed a distribution agreement with Brojaw Inc., to begin distributing its snoring and nasal breathing product Mute into the Taiwanese market.

 
Rhinomed bags $2.1M to expand breathing technology solutions

2017-03-15 proactiveinvestors.com.au
Rhinomed (ASX:RNO) has undertaken a $2.1 million private placement to two U.S. based sophisticated investor groups to fund its retail distribution expansion.

 
Rhinomed to lift cash balance

2017-03-13 proactiveinvestors.com.au
Rhinomed (ASX:RNO) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Rhinomed And The Team Up To Transform Australian Sleep Market

2016-12-07 devicespace
MELBOURNE, Australia, Dec. 7, 2016 /PRNewswire/ -- Australian innovator Rhinomed (ASX:RNO) is seeking to transform the way consumers view sleep by teaming up with sleep giant The Linde Group through its subsidiary BOC Limited.

 
Mute Makes U.S. Debut in Select Walgreens and Duane Reade Stores

2016-05-31 prnewswire
MELBOURNE, Australia, May 31, 2016 /PRNewswire/ -- Rhinomed LTD (ASX:RNO), an Australian nasal and respiratory technology company, is pleased to announce the U.S. debut of its Mute snoring and sleep technology. All four Mute packs (trial, small, medium and large) are now available in select Walgreens and Duane Reade stores across the U.S., including approximately 100 of the chain's locations throughout Manhattan, New York.

 
 

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...